RB1 and endometrioid adenocarcinoma: According to The Cancer Genome Atlas (TCGA) data, 77% of endometrioid carcinomas contain mutations in PTEN, but few alterations in TP53 (1.1%) and the RB pathway, such as upregulation of CCNE1 (none), CDKN2A (3%), E2F1 (2.2%), CDK2 (none), CDK4 (1.1%) and CDK6 (1.1%), and deletion of RB1 (2.2%).